



SCENESSE® data to be presented at European dermatology conference

Baar, Switzerland and Melbourne, Australia, October 8, 2014

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that data from the use of its drug SCENESSE® (afamelanotide 16mg) in clinical trials and special access schemes are being presented at the European Academy for Dermatology and Venereology (EADV) meeting in Amsterdam, held from 8-12 October.

Results from the Phase II US study in vitiligo (CUV102) and clinical experiences of treating erythropoietic protoporphyria (EPP) patients during seven years in Switzerland and Italy are being discussed among specialists and dermatologists at the 'MSH Society Meeting' on October 8.

This is the sixth consecutive year that clinical data from physicians using SCENESSE® have been presented at the EADV, Europe's largest dermatology conference.

- End -

References

Lebwohl M. "Afamelanotide in vitiligo – the first experience". MSH-Society meeting, October 8, 11:40, Room G104.

Minder E. "Update on treatment of erythropoietic protoporphyria with afamelanotide". MSH-Society meeting, October 8, 9:50, Room G104.

Investor contacts:

Australia:	Clinuvel Pharmaceuticals Limited,	T: +61 3 9660 4900
Europe:	Clinuvel AG,	T: +41 41 767 45 45
E:	investorrelations@clinuvel.com	

Media contacts:

Lachlan Hay
Clinuvel Pharmaceuticals Limited
Lachlan.Hay@clinuvel.com

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. Clinuvel's lead compound, SCENESSE® (afamelanotide), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been filed for review by the European Medicines Agency. Based in Melbourne, Australia, Clinuvel has operations in Europe, the US and Singapore.

For more information go to <http://www.clinuvel.com>.

Clinuvel is an Australian biopharmaceutical company focussed on developing its photoprotective drug, SCENESSE® (afamelanotide) for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place